Natera, Inc. (NASDAQ:NTRA – Get Rating) insider Daniel Rabinowitz sold 2,387 shares of the firm’s stock in a transaction that occurred on Monday, January 23rd. The shares were sold at an average price of $41.56, for a total value of $99,203.72. Following the completion of the transaction, the insider now owns 148,853 shares of the company’s stock, valued at $6,186,330.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Daniel Rabinowitz also recently made the following trade(s):
- On Friday, December 23rd, Daniel Rabinowitz sold 476 shares of Natera stock. The shares were sold at an average price of $42.30, for a total value of $20,134.80.
Natera Stock Performance
NTRA opened at $42.94 on Wednesday. The business has a fifty day simple moving average of $39.55 and a 200 day simple moving average of $44.06. The company has a market capitalization of $4.19 billion, a PE ratio of -7.56 and a beta of 1.28. Natera, Inc. has a 1 year low of $26.10 and a 1 year high of $74.82. The company has a debt-to-equity ratio of 0.78, a current ratio of 3.10 and a quick ratio of 2.95.
Analysts Set New Price Targets
NTRA has been the subject of a number of analyst reports. Robert W. Baird decreased their price target on Natera from $72.00 to $65.00 in a research note on Wednesday, November 9th. Piper Sandler restated an “overweight” rating and issued a $70.00 price target on shares of Natera in a research note on Tuesday, January 17th. BTIG Research reduced their target price on Natera from $95.00 to $75.00 in a research note on Wednesday, November 9th. StockNews.com initiated coverage on Natera in a research note on Wednesday, October 12th. They set a “sell” rating for the company. Finally, Raymond James upgraded Natera from a “market perform” rating to an “outperform” rating and set a $58.00 target price for the company in a research note on Wednesday, January 18th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $80.00.
Hedge Funds Weigh In On Natera
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Fred Alger Management LLC raised its holdings in Natera by 21.2% in the 3rd quarter. Fred Alger Management LLC now owns 8,781,346 shares of the medical research company’s stock valued at $384,799,000 after acquiring an additional 1,534,001 shares in the last quarter. Vanguard Group Inc. raised its holdings in Natera by 4.7% in the 3rd quarter. Vanguard Group Inc. now owns 8,312,584 shares of the medical research company’s stock valued at $364,258,000 after acquiring an additional 371,740 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Natera by 9.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 5,472,779 shares of the medical research company’s stock valued at $193,955,000 after acquiring an additional 466,500 shares in the last quarter. State Street Corp raised its holdings in Natera by 20.4% in the 2nd quarter. State Street Corp now owns 3,409,372 shares of the medical research company’s stock valued at $120,828,000 after acquiring an additional 577,106 shares in the last quarter. Finally, Samlyn Capital LLC raised its holdings in Natera by 40.4% in the 3rd quarter. Samlyn Capital LLC now owns 2,277,136 shares of the medical research company’s stock valued at $99,784,000 after acquiring an additional 655,121 shares in the last quarter. 93.81% of the stock is owned by institutional investors and hedge funds.
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
- Get a free copy of the StockNews.com research report on Natera (NTRA)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.